Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.45 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.44 |
| ▸ | KIT | P10721 | 2/20 | 0.42 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.42 |
| ▸ | CKS1B | P61024 | 1/20 | 0.42 |
| ▸ | SKP1 | P63208 | 1/20 | 0.42 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31410416 | 0.85 | KMT2A (0.57) | MEN1KMT2AGPR119TRPV1KIT | |
| SCHEMBL31410432 | 0.85 | KMT2A (0.57) | MEN1KMT2AGPR119TRPV1KIT | |
| SCHEMBL2421442 | 0.84 | MEN1 (0.47) | MEN1KMT2AGPR119TRPV1KIT | |
| SCHEMBL30394316 | 0.84 | MEN1 (0.46) | MEN1KMT2AGPR119TRPV1KIT | |
| SCHEMBL899444 | 0.84 | MEN1 (0.54) | MEN1KMT2AGPR119KITCKS1B | |
| SCHEMBL25209396 | 0.84 | GPR119 (0.47) | MEN1KMT2AGPR119KITCKS1B | |
| SCHEMBL31142996 | 0.84 | KIT (0.46) | MEN1KMT2AGPR119TRPV1KIT | |
| SCHEMBL30223144 | 0.84 | MEN1 (0.54) | MEN1KMT2AGPR119KITCKS1B | |
| SCHEMBL31639750 | 0.84 | KIT (0.46) | MEN1KMT2AGPR119TRPV1KIT | |
| SCHEMBL2416854 | 0.84 | MEN1 (0.46) | MEN1KMT2AGPR119TRPV1KIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8026241-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2011-09-27 | — | — | US | disclosed |
| US-7582761-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2009-09-01 | — | — | US | disclosed |
| US-20090143575-A1 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | BALAN CHENERA | 2009-06-04 | — | — | US | disclosed |
| EP-1551811-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS VANILLOID RECEPTOR LIGANDS | Amgen Inc. (US) | 2005-07-13 | — | — | EP | disclosed |
| US-20040152690-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. | 2004-08-05 | — | — | US | disclosed |
| WO-2004035549-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS VANILLOID RECEPTOR LIGANDS | AMGEN INC. (US) | 2004-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143575-A1 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | TRPV1, TRPV3, TRPV2 | MEN1 3933/4885KMT2A 3344/4885GPR119 112/4885 |
| US-20040152690-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV3, TRPV2 | MEN1 4227/4885KMT2A 3264/4885GPR119 125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.